MANAGEMENT TEAM
Roland Weis, PhD, Head of Operations & CEO
Roland Weis is the Head of Operations & CEO at VALIDOGEN GmbH. Roland completed his graduate in Microbiology at Karl-Franzens-University Graz and his PhD in Molecular Biotechnology at Graz University of Technology. After a post-doctorate at Graz University of Technology in a bilateral project with US-based BioCatalytics, Inc., he acted as authorized representative and scientific director of BioCatalytics Europe GmbH. He joined VALIDOGEN, known then as VTU Technology, to build up the UNLOCK PICHIA® platform and head the operational team for high throughput protein production with Pichia pastoris. Under Roland's technological leadership, and with more than 20 years of experience in the field of Pichia protein expression, VALIDOGEN has grown into a global leading Pichia protein expression service provider.
Thomas Purkarthofer, PhD, Head of Business Development & CEO
Thomas Purkarthofer, PhD, serves as the Head of Business Development and CEO at VALIDOGEN GmbH. He earned his PhD in Chemistry from Graz University of Technology and brings experience in industrial biotechnology, having led and contributed to several international R&D projects prior to joining VALIDOGEN (formerly known as VTU Technology).
Since joining the company, Thomas has spearheaded the establishment and expansion of the business development division. He has been instrumental in the commercialization of VALIDOGEN’s proprietary Pichia pastoris protein expression platform, fostering strong global customer relationships.
In addition to his business development expertise, Thomas is an active member of VALIDOGEN’s R&D team, contributing to innovative advancements in the field. Since 2021, he has also served as one of the managing directors, further driving the company’s strategic growth and success.
Michael Koncar, PhD, Founder
Michael Koncar is a distinguished entrepreneur and seasoned executive, currently serving as the CEO of KonValue Holding GmbH. He is the founder of VALIDOGEN GmbH and founder and shareholder of VTU Engineering. Michael earned his PhD in Process Engineering from Graz University of Technology, showcasing his strong academic foundation in the field. His entrepreneurial journey began in 1990 with the establishment of VTU Engineering. In 2008, he founded VTU Technology, a company later rebranded as VALIDOGEN GmbH in October 2018, further highlighting his commitment to innovation and growth.
Beyond his primary ventures, Michael is an active shareholder in multiple pioneering companies, reflecting his dedication to advancing technology and driving industrial progress.
Roland Weis, PhD, Head of Operations & CEO
Roland Weis is the Head of Operations & CEO at VALIDOGEN GmbH. Roland completed his graduate in Microbiology at Karl-Franzens-University Graz and his PhD in Molecular Biotechnology at Graz University of Technology. After a post-doctorate at Graz University of Technology in a bilateral project with US-based BioCatalytics, Inc., he acted as authorized representative and scientific director of BioCatalytics Europe GmbH. He joined VALIDOGEN, known then as VTU Technology, to build up the UNLOCK PICHIA® platform and head the operational team for high throughput protein production with Pichia pastoris. Under Roland's technological leadership, and with more than 20 years of experience in the field of Pichia protein expression, VALIDOGEN has grown into a global leading Pichia protein expression service provider.
Thomas Purkarthofer, PhD, Head of Business Development & CEO
Thomas Purkarthofer, PhD, serves as the Head of Business Development and CEO at VALIDOGEN GmbH. He earned his PhD in Chemistry from Graz University of Technology and brings experience in industrial biotechnology, having led and contributed to several international R&D projects prior to joining VALIDOGEN (formerly known as VTU Technology).
Since joining the company, Thomas has spearheaded the establishment and expansion of the business development division. He has been instrumental in the commercialization of VALIDOGEN’s proprietary Pichia pastoris protein expression platform, fostering strong global customer relationships.
In addition to his business development expertise, Thomas is an active member of VALIDOGEN’s R&D team, contributing to innovative advancements in the field. Since 2021, he has also served as one of the managing directors, further driving the company’s strategic growth and success.
Michael Koncar, PhD, Founder
Michael Koncar is a distinguished entrepreneur and seasoned executive, currently serving as the CEO of KonValue Holding GmbH. He is the founder of VALIDOGEN GmbH and founder and shareholder of VTU Engineering. Michael earned his PhD in Process Engineering from Graz University of Technology, showcasing his strong academic foundation in the field. His entrepreneurial journey began in 1990 with the establishment of VTU Engineering. In 2008, he founded VTU Technology, a company later rebranded as VALIDOGEN GmbH in October 2018, further highlighting his commitment to innovation and growth.
Beyond his primary ventures, Michael is an active shareholder in multiple pioneering companies, reflecting his dedication to advancing technology and driving industrial progress.